Intellectual Property and Data Rights
Overview
To maintain a competitive advantage, companies must rigorously protect rights in their advanced technology and computer software. This is particularly true for any company that does business at the prime contract, subcontract, or grant level with the federal government because the government obtains broad rights when intellectual property is developed, conceived, or reduced to practice with its money. We are one of the few firms with lawyers that focus on this field — lawyers who have literally written the book on contractors' rights in computer software and technical data.
Contacts
Partner
She/Her/Hers
Insights
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Firm News | 9 min read | 06.06.24
Event | 05.09.23 - 05.10.23
39th Annual Ounce of Prevention Seminar—Government Contracting Amidst a Global Shake-Up
Webinar | 03.15.23
Insights
Professionals
Insights
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Firm News | 9 min read | 06.06.24
Event | 05.09.23 - 05.10.23
39th Annual Ounce of Prevention Seminar—Government Contracting Amidst a Global Shake-Up
Webinar | 03.15.23
